These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
130 related articles for article (PubMed ID: 31397906)
41. Alteration of cardiac progenitor cell potency in GRMD dogs. Cassano M; Berardi E; Crippa S; Toelen J; Barthelemy I; Micheletti R; Chuah M; Vandendriessche T; Debyser Z; Blot S; Sampaolesi M Cell Transplant; 2012; 21(9):1945-67. PubMed ID: 22513051 [TBL] [Abstract][Full Text] [Related]
42. Laminin-111 protein therapy enhances muscle regeneration and repair in the GRMD dog model of Duchenne muscular dystrophy. Barraza-Flores P; Fontelonga TM; Wuebbles RD; Hermann HJ; Nunes AM; Kornegay JN; Burkin DJ Hum Mol Genet; 2019 Aug; 28(16):2686-2695. PubMed ID: 31179490 [TBL] [Abstract][Full Text] [Related]
43. Alternative dystrophin gene transcripts in golden retriever muscular dystrophy. Schatzberg SJ; Anderson LV; Wilton SD; Kornegay JN; Mann CJ; Solomon GG; Sharp NJ Muscle Nerve; 1998 Aug; 21(8):991-8. PubMed ID: 9655116 [TBL] [Abstract][Full Text] [Related]
44. Non-Targeted Metabolomics Analysis of Golden Retriever Muscular Dystrophy-Affected Muscles Reveals Alterations in Arginine and Proline Metabolism, and Elevations in Glutamic and Oleic Acid In Vivo. Abdullah M; Kornegay JN; Honcoop A; Parry TL; Balog-Alvarez CJ; O'Neal SK; Bain JR; Muehlbauer MJ; Newgard CB; Patterson C; Willis MS Metabolites; 2017 Jul; 7(3):. PubMed ID: 28758940 [TBL] [Abstract][Full Text] [Related]
45. In vivo stem cell tracking using scintigraphy in a canine model of DMD. Barthélémy I; Thibaud JL; de Fornel P; Cassano M; Punzón I; Mauduit D; Vilquin JT; Devauchelle P; Sampaolesi M; Blot S Sci Rep; 2020 Jun; 10(1):10681. PubMed ID: 32606364 [TBL] [Abstract][Full Text] [Related]
46. Microvessel density in muscles of dogs with golden retriever muscular dystrophy. Nguyen F; Guigand L; Goubault-Leroux I; Wyers M; Cherel Y Neuromuscul Disord; 2005 Feb; 15(2):154-63. PubMed ID: 15694137 [TBL] [Abstract][Full Text] [Related]
47. NBD delivery improves the disease phenotype of the golden retriever model of Duchenne muscular dystrophy. Kornegay JN; Peterson JM; Bogan DJ; Kline W; Bogan JR; Dow JL; Fan Z; Wang J; Ahn M; Zhu H; Styner M; Guttridge DC Skelet Muscle; 2014; 4():18. PubMed ID: 25789154 [TBL] [Abstract][Full Text] [Related]
48. Physical therapy assessment tools to evaluate disease progression and phenotype variability in Golden Retriever muscular dystrophy. Gaiad TP; Silva MB; Silva GC; Caromano FA; Miglino MA; Ambrósio CE Res Vet Sci; 2011 Oct; 91(2):188-93. PubMed ID: 21315399 [TBL] [Abstract][Full Text] [Related]
49. Human adipose-derived mesenchymal stromal cells injected systemically into GRMD dogs without immunosuppression are able to reach the host muscle and express human dystrophin. Vieira NM; Valadares M; Zucconi E; Secco M; Bueno CR; Brandalise V; Assoni A; Gomes J; Landini V; Andrade T; Caetano HV; Vainzof M; Zatz M Cell Transplant; 2012; 21(7):1407-17. PubMed ID: 23168016 [TBL] [Abstract][Full Text] [Related]
50. Quantitative proteome profiling of dystrophic dog skeletal muscle reveals a stabilized muscular architecture and protection against oxidative stress after systemic delivery of MuStem cells. Lardenois A; Jagot S; Lagarrigue M; Guével B; Ledevin M; Larcher T; Dubreil L; Pineau C; Rouger K; Guével L Proteomics; 2016 Jul; 16(14):2028-42. PubMed ID: 27246553 [TBL] [Abstract][Full Text] [Related]